Blau is a mid-sized Brazilian pharmaceutical manufacturer focused on hospital and institutional drug supply, with five manufacturing plants and active presence across Latin America and the US. The tech stack is dominated by regulatory and operations infrastructure (HPLC, LIMS, SAP, Salesforce, IQVIA) — typical of a compliance-heavy manufacturing business — but pain points cluster around supply-chain visibility (sell-in/sell-out data flow, S&OP/S&OE integration, supplier onboarding) and quality deviations. Hiring is accelerating across manufacturing and sales, suggesting either capacity expansion or a push to modernize commercial processes.
Blau Farmacêutica manufactures high-complexity pharmaceuticals across immunology, hematology, oncology, nephrology, infectious disease, and anesthesiology. The company operates five drug-manufacturing facilities and an active pharmaceutical ingredient (API) plant in Brazil, all equipped with integrated monitoring and control systems meeting international regulatory standards. Sales and distribution reach seven Latin American countries plus the United States (via Hemarus, a plasma-collection network). The company sells primarily into institutional and hospital channels, with a portfolio of proprietary branded drugs.
Manufacturing and quality systems (HPLC, LIMS), ERP (SAP), CRM (Salesforce), commercial intelligence (IQVIA), and IT infrastructure (Windows Server, VMware, Active Directory, Veeam Backup, Zabbix monitoring).
Headquartered in Cotia, São Paulo, Brazil. Manufacturing and sales operations span Argentina, Chile, Colombia, Ecuador, Mexico, Peru, Uruguay, and the United States.
Other companies in the same industry, closest in size